EssilorLuxottica acquires RetinAI, accelerating transformative AI and data-powered eye health solutions

NKF has acted as lead counsel to EssilorLuxottica on the acquisition of Ikerian AG announced on 15 October 2025.

Ikerian is a Swiss headquartered health technology company, operating under the RetinAI brand, specializing in AI and data management in eyecare. It develops advanced tools to collect, process and grade large-scale retinal images and biomarker datasets. The RetinAI Discovery platform applies AI models to support diagnosis and monitoring of disease progression – including age-related macular degeneration (AMD), glaucoma and diabetic retinopathy – enabling more accurate and timely decisions in managing eye diseases. At the same time, RetinAI partners with pharmaceutical companies and research organizations that leverage proprietary real-world evidence to accelerate clinical studies and drug development.

EssilorLuxottica (Euronext Paris) is a global leader in the design, manufacturing and distribution of advanced vision care products, eyewear and med-tech solutions.

The NKF team was led by Corporate/M&A partner Philippe Weber and senior associate Samuel Hochstrasser, working with associate Manuel Hirlinger and junior associate Sandja Kozina (all Corporate/M&A), partner Janine Reudt-Demont and associate Luisa Egli (both Life Sciences, IP/IT/Data Protection).